Specify a stock or a cryptocurrency in the search bar to get a summary
Edgewise Therapeutics Inc
EWTXEdgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company also develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The Company was incorporated in 2017 and is headquartered in Boulder, Colorado. Address: 3415 Colorado Avenue, Boulder, CO, United States, 80303
Analytics
WallStreet Target Price
26.4 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures EWTX
Dividend Analytics EWTX
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History EWTX
Stock Valuation EWTX
Financials EWTX
Results | 2019 | Dynamics |